Podcasts about Nobel Prize

What if one molecule could help you live longer, think clearer, and recover faster — and it's backed by a Nobel Prize?   In this episode of the Thrive State Podcast, Dr. Kien Vuu (Doctor V) sits down with Chris Burres, research scientist and founder of MyVitalC, to unpack the science behind Carbon 60 (C60) — a molecule so powerful it increased the lifespan of test rats by 90% in a peer-reviewed study.   Chris breaks down the connection between oxidative stress, aging, and how ESS60 (a purified version of C60) could be the key to unlocking greater human performance, mental clarity, and cellular longevity.  

Please enjoy this re-release of a past episode of For the Ages. New episodes will return Fall 2025. Bestselling author Walter Isaacson, in conversation with David M. Rubenstein, discusses the life and work of the Nobel Prize-winning Jennifer Doudna who, with her collaborators, created a DNA-editing tool with the power to revolutionize human health. Recorded on  February 19, 2021 

Nobel Prize-winning Italian author Grazia Deledda's "The Open Door"

Fresh back from London! In this episode, Eric Newcomer reunites with co-hosts James Wilsterman and Max Child of Volley to dive into the best moments from the Cerebral Valley AI Summit.From buzzy startup founders to incumbent innovators, the London event showcased a rapidly evolving AI landscape. But what stood out most? Eric, James, and Max break down their favorite clips and debate the key questions driving the industry right now:Models vs. Applications: Are we back in a “models win” moment?The Uber Dilemma: Why did Uber spin off its self-driving technology instead of competing with Waymo? Dara Khosrowshahi's reasoning sparks a heated debate about platform dynamics, marketplace power, and whether Uber made the right call.Figma's IPO Moment: With their S-1 filing just days after the summit, Dylan Field defended Figma's AI strategy and new product launches.The Science of Discovery: Can AI models trained on “boring rule followers” actually make Nobel Prize-worthy breakthroughs?The End of Reading?: Synthesia's CEO made the boldest prediction yet — that kids won't read anymore, and video will replace text entirely. The hosts wrestle with what this means for human intelligence and whether writing really is thinking.The next Cerebral Valley AI Summit returns to San Francisco on November 12th!Timestamps08:21 Uber's Self-Driving Strategy and Market Positioning16:56 Figma's IPO Bear and Bull case26:17 Harry Stebbings' Interview Insights with Granola's CEO32:11 Exploring AI's Role in Scientific Discovery38:26 The Impact of AI on Reading and Writing

If you care about longevity, brain optimization, sexual performance, or metabolism, this molecule changes everything. Host Dave Asprey sits down with nitric oxide pioneer Dr. Nathan Bryan to reveal why this overlooked molecule controls your blood flow, mitochondrial energy, neuroplasticity, insulin response, and even your libido. You'll learn how nitric oxide acts as a master switch for human performance and why the medical system has ignored it for decades. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Dr. Nathan Bryan is a world-renowned expert in nitric oxide biochemistry with over 20 years of clinical research, multiple patents, and collaborations with Nobel Prize-winning scientists. His groundbreaking work forms the foundation for modern functional medicine protocols targeting blood flow, metabolism, cognitive enhancement, and mitochondrial upgrades. You'll learn: • How nitric oxide drives mitochondria, metabolism, and human performance • Why most nitric oxide supplements fail and how to spot real ones • The critical role nitric oxide plays in brain optimization, libido, and insulin signaling • How poor oral health, statins, and PPIs can kill nitric oxide production • What nitric oxide has to do with sleep optimization, aging, and disease prevention • How to stack nitric oxide with fasting, ketosis, nootropics, red light, and supplements • Why “Smarter Not Harder” starts with nitric oxide fueled upgrades This episode is essential listening for anyone into biohacking, cold therapy, functional medicine, or RFK-style medical freedom. You'll walk away with practical tools to boost nitric oxide naturally, prevent dysfunction, and optimize your biology whether you're on a carnivore diet or just looking for an edge. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade is the top podcast for people who want to take control of their biology, extend their longevity, and optimize every system in the body and mind. Each episode features cutting-edge insights in health, performance, neuroscience, supplements, nutrition, hacking, emotional intelligence, and conscious living. Episodes are released every Tuesday and Thursday, where Dave asks the questions no one else dares, and brings you real tools to become more resilient, aware, and high performing. Get Nitric Oxide products for 10% off with code ‘Dave': https://bit.ly/Nitric-Oxide-Product SPONSORS: Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off. Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. Resources: • Nathan's Website: https://www.n1o1.com • Nathan's YouTube: https://www.youtube.com/channel/UCtftGy8e0r9DO8ActcyGi4w • Dave Asprey's Website: https://daveasprey.com • Danger Coffee: https://dangercoffee.com/DAVE15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: • 00:00 Trailer • 01:03 Intro • 01:15 Why Medicine Ignores Nitric Oxide • 01:59 What Nitric Oxide Does in the Body • 04:46 How the Body Makes Nitric Oxide • 07:12 Diet's Impact on NO Levels • 13:28 Why Most NO Supplements Fail • 19:32 Personalized Biohacking with NO • 22:33 How Medicine Misses the Mark • 30:40 Oral Health and Nitric Oxide • 31:30 Mouthwash Kills Your Microbiome • 32:28 The Problem with Fluoride • 33:25 Better Toothpaste for NO • 33:49 NO's Role in Energy and Healing • 34:17 Blood Pressure and NO • 35:29 NO and Sexual Performance • 37:09 NO and COVID Recovery • 40:50 Brain Fog and NO Deficiency • 49:01 Carnivore, Sugar, and NO • 50:11 Why You Still Need NO Supplements • 54:19 Final Takeaways See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Steve Hofstetter joins us in the Acement for a great conversation. Steve has over 200m views on YouTube, he's been nominated for a Nobel Prize, had a Number 1 Comedy Album on Apple, and his book "Ginger Kid" was a Top 5 pick on Amazon. Just to name a couple things. Best part is, even an accomplished comedian like Steve has a Funny Bad Gig Story. Check out Steve at https://www.stevehofstetter.com/Check out Ace at https://www.aceaceto.lol/ and Scott at https://scotthigginscomedy.com/

Serge Haroche won the Nobel Prize in Physics in 2012 along with American physicist David Wineland for their work on studying quantum phenomena when matter and light interact. The study of matter at its most fundamental level may be hard for many people to wrap their heads around, but as Haroche tells FRANCE 24, study in this field has led to the inventions of life-changing devices. "The GPS is based on atomic clocks; magnetic resonance imaging, which is used in medicine, is also based on quantum phenomena."

This book will introduce you to yourself in a new way. It will transform how you thnk about yourself and help you recognize your own self-limitimg beliefs about who you are and can be. It is the author's story but it is also all of our story. The book moves through time from right after World War II, when the author was born, through the fifties, sixties and seventies as she grows up, eventually becoming a Jungian psychologist in the eighties. You have a front-row seat as you travel through the decades right up to the present witnessing Susan's sometimes harrowwing but always wondrous experiences with the invisible world.  Astral travel, angel visits, travel to the life between life realm, encounters with ghosts, conversations with the dead, including Jung, out of body experiences, possession by a dark being, dream realities, and visits to other dimensions, are some of the things she will share with you in A Jungain Understanding of Transcendent Experiences. By 2024 Susan realizes that the nature of reality is One Consciousness supporting all of us, or as Nobel Prize winning quantum phyisicist, Erwin Schrodinger, put it: "The number of minds in the universe is One."  We all have access to this Mind. This realization offers us freedom to move beyond hopelessness and negative thinking, to harness the power of this Mind to think the thoughts which create the experiences we desire. What we think, we create.This book is part of a series of books by different authors sharing their perspectives on the paranormal. Gavin Davies conceived the idea and invited the rest of us. The title all the books begins with Paranormal Perspectives: -- and then the author's subttitle. That should make it possible to find all of them on Amazon. I hope you enjoy the whole series. The first bunch will be released October 30, 2024. I enjoyed writing this more than any other book I've written.https://www.susanplunket.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/earth-ancients--2790919/support.

In this episode of Words & Numbers, James and Ant announce their new partnership with CiVL and reflect on the state of modern life. Using Jurassic World and a Nobel Prize winner's comments as a springboard, they unpack the economics of innovation, incentives, and monopolies. They take on popular claims that life has gotten worse—breaking down the real costs of housing, cars, and higher education over time—and challenge the doom-and-gloom narrative with hard data and perspective. The debut of the new “So What?” segment offers concrete takeaways: count your blessings, question the media's distortions, and don't believe everything “everybody knows.” Words and Numbers is a CiVL Original Podcast. Join CiVL for member-exclusive access to our show, bonus content, and live Q&As. https://civl.com/ Get 50% off your annual subscription with code: WORDSANDNUMBERS Get Your Copy of Cooperation and Coercion Now! http://www.cooperationandcoercion.com See More Ant and James! http://www.wordsandnumbers.org Show Your Support for Words & Numbers at Patreon https://www.patreon.com/wordsandnumbers Quick Hits https://www.jurassicworld.com https://english.elpais.com/science-tech/2025-07-04/charles-rice-nobel-prize-winner-in-medicine-its-a-crime-that-a-drug-exists-that-could-cure-everyone-yet-not-everybody-has-access-to-it.html https://www.thetimes.com/world/latin-america/article/gringo-go-home-why-mexico-is-turning-against-us-immigrants-cmq2qsv2j Foolishness of the Week https://www.yahoo.com/news/fema-removed-dozens-camp-mystic-111716138.html Words & Numbers Backstage https://youtu.be/i73H047bID8?si=zUTcXrBYDolwTVgl https://fred.stlouisfed.org/series/MSPUS https://fred.stlouisfed.org/series/LES1252881500Q https://www.bankrate.com/real-estate/average-home-size/#space https://fred.stlouisfed.org/series/CUUR0000SETA01 More James at Smoke & Stories https://www.youtube.com/playlist?list=PLjILow4-ZJpBV-NnmSusZJ_vCuzKUJ4Ig More Ant on YouTube https://www.youtube.com/antonydavies Let Us Know What You Think mailto:wordsandnumberspodcast@gmail.com Antony Davies on Twitter https://twitter.com/antonydavies James R. Harrigan on Twitter https://twitter.com/JamesRHarrigan #AntonyDavies #JamesRHarrigan #WordsAndNumbers #economics #government #politics #policy #libertarian #classicalliberal #podcast #educational Learn more about your ad choices. Visit podcastchoices.com/adchoices

We're back with another quick collection of Trump and the havoc he wreaked and the mayhem he mustered in the last few days.What do Rosie O'Donnell, tariffs, Jeffrey Epstein, and the Nobel Prize have in common?It all on this new episode of LFMO on THIS WEEK IN TRUMPSHOW NOTES:YOU LOOK LIKE A WINNERI'm easy.  If you want a free $50 gift card to the amazing ABT ELECTRONICS (and a lot more) at ABT.COM...its easy. Just send me this week's phrase that pays with your regular home address to thecochranshow@gmail.comThe phrase is:"hey Steve, where's mine?"Let's Survive 2025 Together. With a cool new shirt and hat! Get yours here.Thanks to our sponsor, ABT Electronics. Get $25 off your next purchase of $150 or more by using the promo code COCHRAN2025 online or in person!Watch This Episode on our Live From My Office YouTube ChannelFollow me on Substack.With each new episode, the first three listeners thatemail me“SURVIVE 2025!” will be eligible to win a $25 ABT Giftcard as long as you include your mailing address and that phrase!Don't forget to subscribe to listen to “Live From My Office” wherever you get your podcasts, and e-mail the show with any questions, comments, or plugs for your favorite charity!

Paul Ollinger quit his job at Facebook to chase his comedy dream. (Don't ever do that.) This highly unprofitable decision has allowed him to headline major clubs like Carolines on Broadway, Cobbs (SF), and Zanies (Nashville and Chicago). He has performed at the Hollywood Improv and Comedy Cellar, and headlined his own show in the 2024 New York Comedy Festival. Paul is the host of the Reasonably Happy podcast, on which he explores the connection between money, happiness, work, and meaning in conversations with some of the world's most interesting people. Previous guests include LL COOL J, Deepak Chopra, Judd Apatow, Paul Shaffer, and winners of the Nobel Prize, Heisman Trophy, and Olympic gold medals. He has just published a collection of essays, also titled Reasonably Happy, in which he shares humorous, thoughtful, and sometimes touching insights from over 200 of these interviews. Podcast Sponsor: Summit Leadership Group Summit Leadership Group transforms organizations by developing bold, agile leaders who inspire performance and lead with purpose. Through tailored coaching and immersive training, we ignite lasting growth where it matters most—at the intersection of people, culture, and results. To know more about Paul visit his website: www.paulollinger.com

It's hard to believe that Fitzcarraldo Editions has only existed for ten years; during that short time, they have published a remarkable selection of books (gathering four Nobel Prizes between them), and their iconic blue and white covers have become a mainstay of the bookshop. To celebrate their first decade, Fitzcarraldo are publishing some of their best-loved titles in hardback, limited edition form. Brian Dillon and Kate Briggs will be at the shop to discuss their books in this series: Dillon's Essayism (a gathering together of his loose trilogy on the intimate and abstract pleasures of reading and looking), and Briggs' This Little Art, a fresh, fierce and timely meditation on literary translation. The conversation will be chaired by Helen Charman, whose political history of motherhood, Mother State, came out earlier this year from Penguin.

In this episode of Disruptors x CDL: The Innovation Era, hosts John Stackhouse, Senior VP of RBC, and Sonia Sennik, CEO of Creative Destruction Lab, dive into one of the most transformative technologies of our time: Artificial Intelligence. With the potential to revolutionize industries from healthcare to energy, AI is reshaping the global economy — and Canada is both a leader in research and a laggard in adoption.This week, Geoffrey Hinton, Professor at the University of Toronto, was awarded the Nobel Prize in Physics for his research in artificial intelligence that began in 1987.Join John and Sonia as they discuss Canada's AI ecosystem and the country's challenges in keeping pace with global AI adoption. They're joined by three visionary guests: Sheldon Fernandez, CEO of Darwin AI, Kory Mathewson, Senior Research Scientist at Google DeepMind, and Gillian Hadfield, a Schmidt Sciences AI2050 Senior Fellow. Together, they explore the opportunities and barriers in AI adoption, the creative applications of AI, and the role Canada must play in the future of AI.This episode is packed with insights for business leaders, policymakers, and anyone curious about how AI is changing our world. Whether you're an AI enthusiast or a skeptic, this episode will challenge your thinking on the role of technology in shaping the future.Tune in to learn how AI is both an opportunity and a responsibility, and how Canada can lead the charge in this new innovation era.Sign up to receive RBC Thought Leadership's newsletter, flagship reports and analysis on the forces shaping Canadian business and the economy.

Heartbreaking was the only word that could be used to describe the death of a 10-month-old baby in Perth. What was less clear cut is the question that was posed to the judge - was the baby boy’s death an accident, or was he murdered by his father? Judith Fordham has been lauded as one of Western Australia’s most high-profile criminal lawyers, but her dual expertise in law and forensics sets her apart from her colleagues. In this episode with former Crime Insider Forensics host, Kathryn Fox, hear about one of the most divisive areas in both forensic science and the law - "shaken baby syndrome". This episode references child abuse and infant loss. If you or someone you know is experiencing, or at risk of experiencing, domestic, family or sexual violence, call 1800RESPECT on 1800 737 732, text 0458 737 732 or visit 1800RESPECT.org.au for online chat and video call services. For support relating to infant loss, contact Red Nose Grief and Loss on 1300 308 307 or visit rednosegriefandloss.org.au. See omnystudio.com/listener for privacy information.

For decades, evolutionary biologists considered non-coding regions of DNA as evolutionary junk, a paradigm that long dissuaded researchers from studying these little-understood portions of the genome. But a series of discoveries starting in 2008 has forced a major change in thinking about so-called "junk" DNA. Many examples of function have since been identified for the non-coding regions of DNA, and more are being uncovered each year. On this ID The Future, Dr. Casey Luskin reports on a pair of American biologists who were recently awarded the Nobel Prize for their discovery of function in what was previously considered junk DNA. Source

Was "junk DNA" ever really junk—or did science just need to catch up with design?  In this episode of All Rise, we talk to Dr. Fazale Rana (biochemist and President & CEO at Reasons to Believe) to dive into one of the most groundbreaking scientific reversals in recent history: the 2024 Nobel Prize awarded for discoveries showing that so-called “junk DNA” is functional and essential.  For decades, large portions of the human genome were written off as useless leftovers of evolution. But was that ever good science—or just bad theology in disguise? Fuz Rana walks us through the history of this idea, why many Christian scientists and intelligent design theorists questioned it from the beginning, and how new discoveries are forcing a complete rethinking of what our DNA says about purpose, design, and even God.  Is this the death of the “junk DNA” myth? What does it mean for Darwinian evolution? And how should Christians respond to this scientific turning point?  Whether you're a skeptic, a believer, or just curious about what your genes are really saying, this conversation will give you a fresh look at the intersection of science, faith, and design.    Resources mentioned in this podcast:  George Haraksin and Krista Bontrager (eds.), Revealing God in Science: https://a.co/d/24u5RzX   Other resources mentioned are forthcoming.    

【欢迎订阅】 每天早上5:30，准时更新。 【阅读原文】 标题：‘Playing the Man': Global Diplomacy in the Trump Era Is All About Flattery 正文：Prime Minister Benjamin Netanyahu of Israel handed a letter to President Trump nominating him for the Nobel Peace Prize. But it's not clear whether stroking the president's ego has long-lasting effects. The flattery was as obvious as it was seemingly effective. Seated at a dinner table in the Blue Room of the White House on Monday, Prime Minister Benjamin Netanyahu handed President Trump a piece of paper. “I want to present to you, Mr. President, the letter I sent to the Nobel Prize committee,” Mr. Netanyahu said, with news cameras rolling. “It's nominating you for the Peace Prize. It's well deserved, and you should get it.” Mr. Trump declared the gesture “very meaningful,” though he has long said he believes the Nobel committee would never give him the prize. 知识点：Israel /ˈɪzreɪl/，n. a country in the Middle East, known for its historical and religious significance.（以色列，中东国家，以其历史和宗教意义著称） • Israel is located in the Middle East.以色列位于中东地区。 获取外刊的完整原文以及精讲笔记，请关注微信公众号「早安英文」，回复“外刊”即可。更多有意思的英语干货等着你！ 【节目介绍】 《早安英文-每日外刊精读》，带你精读最新外刊，了解国际最热事件：分析语法结构，拆解长难句，最接地气的翻译，还有重点词汇讲解。 所有选题均来自于《经济学人》《纽约时报》《华尔街日报》《华盛顿邮报》《大西洋月刊》《科学杂志》《国家地理》等国际一线外刊。 【适合谁听】 1、关注时事热点新闻，想要学习最新最潮流英文表达的英文学习者 2、任何想通过地道英文提高听、说、读、写能力的英文学习者 3、想快速掌握表达，有出国学习和旅游计划的英语爱好者 4、参加各类英语考试的应试者（如大学英语四六级、托福雅思、考研等） 【你将获得】 1、超过1000篇外刊精读课程，拓展丰富语言表达和文化背景 2、逐词、逐句精确讲解，系统掌握英语词汇、听力、阅读和语法 3、每期内附学习笔记，包含全文注释、长难句解析、疑难语法点等，帮助扫除阅读障碍。

Please join my mailing list here

Congratulating a Binghamton Nobel Prize winner

* A Whole Lot Moore: Peter W. Moor, ThD is a Christian master metallurgist listed as "inventor" in patents held by U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public. * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists! * E-PLat - (The Simhony/EPOLA): RSR is suggesting a name for the E-PLat!! Hear how Menahem Simhony is the father of a scientifically satisfactory description of what "space" is likely made of. Originally called the EPOLA, for the "Electron/Positron Lattice," we're suggesting E-PLat to avoid confusion with a certain virus! You'll have to listen to all 4 parts of the interview to form your opinion on whether or not the EPOLA/E-PLat makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe. * Deriving $10,000.00: ... and quite possibly a Nobel Prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constatn "G" based on the Natural Physics and Structure of the Simhony/EPOLA Model of the Space Vaccuum. (Pre-register this prize right here)

* A Whole Lot Moore: Peter W. Moor, ThD is a Christian master metallurgist listed as "inventor" in patents held by U.S. Steel. Pete began speaking to Churches on Science and Evolution in 1970. His more recent work has been to help fund organizations that do scientific creation research and those who present that evidence to the public. * Aether or: ...relative nonsense. Hear a brief history, and then, not only criticisms of, but an alternate theory to Einstein's rather ridiculous postulates regarding time and space. Hear how Einstein not only dethroned Newtonian physics, but how his relativistic thinking has infected the minds of otherwise relatively smart creationists! * E-PLat - (The Simhony/EPOLA): RSR is suggesting a name for the E-PLat!! Hear how Menahem Simhony is the father of a scientifically satisfactory description of what "space" is likely made of. Originally called the EPOLA, for the "Electron/Positron Lattice," we're suggesting E-PLat to avoid confusion with a certain virus! You'll have to listen to all 4 parts of the interview to form your opinion on whether or not the EPOLA/E-PLat makes more sense to you than Einstein's "purely mathematical" description of a relativistic universe. * Deriving $10,000.00: ... and quite possibly a Nobel Prize! RSR and Dr. Moore are offering a prize of $10,000.00 to the first person to submit an acceptable technical derivation of the Gravitational Constatn "G" based on the Natural Physics and Structure of the Simhony/EPOLA Model of the Space Vaccuum. (Pre-register this prize right here)  

NB: Oops, I meant 18th century. Also, Michael Haneke is Austrian after all.SLEERICKETS is a podcast about poetry and other intractable problems. My book Midlife now exists. Buy it here, or leave it a rating here or hereFor more SLEERICKETS, subscribe to SECRET SHOW, join the group chat, and send me a poem for Listener Crit!Leave the show a rating here (actually, just do it on your phone, it's easier). Thanks!Wear SLEERICKETS t-shirts and hoodies. They look good!SLEERICKETS is now on YouTube!For a frank, anonymous critique on SLEERICKETS, subscribe to the SECRET SHOW and send a poem of no more 25 lines to sleerickets [at] gmail [dot] com Some of the topics mentioned in this episode:– Toni Morrison's 1993 Nobel Prize lecure– Leopards in the Temple" by Franz Kafka (couldn't find any good links, so here's the text Mark copy-pasted to me: “Leopards break into the temple and drink to the dregs what is in the sacrificial pitchers; this is repeated over and over again; finally it can be calculated in advance, and it becomes a part of the ceremony.“)– Returning the Sword to the Stone by Mark Leidner– Mark's Substack: Opaque Hourglass– Recitatif by Tony Morrison– Funny Games (1997 & 2007)– Hamlet– Julius Caesar– Jack Handey– Andy Kaufman– Plato– The Gettysburg Address– Amleth– The Tower of Babel– The Tree of the Knowledge of Good and Evil– Harold Pinter's 2005 Nobel Prize lecture– Chelsey Minnis– Juvenilia by Hera Lindsay Bird– A Field of Telephones by Zach Savich– Dogs of War by Mark LeidnerFrequently mentioned names:– Joshua Mehigan– Shane McCrae– A. E. Stallings– Ryan Wilson– Morri Creech– Austin Allen– Jonathan Farmer– Zara Raab– Amit Majmudar– Ethan McGuire– Coleman Glenn– Chris Childers– Alexis Sears– JP Gritton– Alex Pepple– Ernie Hilbert– Joanna PearsonOther Ratbag Poetry Pods:Poetry Says by Alice AllanI Hate Matt Wall by Matt WallVersecraft by Elijah BlumovRatbag Poetics By David Jalal MotamedAlice: In Future PostsBrian: @BPlatzerCameron: Minor TiresiasMatthew: sleerickets [at] gmail [dot] comMusic by ETRNLArt by Daniel Alexander Smith

Tom boldly declares his opposition to a national dress code, which no one has yet proposed but better safe than sorry. Scott proposes he recieve for this a Nobel Prize.

Why do we die? Do we have to? Neil deGrasse Tyson, Chuck Nice, and Gary O'Reilly explore the paradox of death, the science of aging, and the search for immortality with Nobel Prize-winning structural biologist Venki Ramakrishnan.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Erick Schnell, Joey T, Nick Fortin, Karen Harbert, Jacob Kirkpatrick, Gunther Hammel, Frankie Blooding, Cynthia Maloy, Davlat Sirojitdinov, Abram Pousada, Adam Wyler, Greg Anderson, Soleful, Vlad lucha, Arvind Sridhar, thomas maigler, Morgan Wireman, Robey Neeley, Isaiah Fox, Volodymyr, BB, Eric Hilgendorf, Gabe B., Josh Emery, Devon Hen, Tiffany Alisa Boggs, Carmine Ciccone, Armstrong Manhães, Chris Sedunary, Chihiro, Roberto Medeiros, Sanaz Mitchell, Greg Wilson, Robert, Matthew Synco Sr., Meiby Yeras, Juraj Belanji, Katherine Yarbrough, Pedro, Sarah Lippert, Conor Doherty, Evgeny Semiletov, Ranjana Ranjana, Umar Cheema, ashwin patti, Grant Norman, Starry-eyed mama, Bob Rueter, Andrew, Peter Rhomberg, Brent Linford, and Dominic Consiglio for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus.

Today's Lake and Shed framed conversation is about J. K. Rowling's second Cormoran Strike novel, The Silkworm. Nick and John discuss the date Rowling claims to have had her Lake inspiration for Silkworm, the first book idea she had for the series, and what that would mean, if true. The ‘Lake' point that Nick reveals is the probable identity of ‘Jenkins,' the mystery person to whom Strike 2 is dedicated, a revelation consequent to no little detective work (and a very close reading of Louisa May Alcott!). He also discusses some real-life literary infighting in contemporary London that might have been lifted from the pages of Silkworm. John argues that this ur-novel of the series, its point of conception, is Rowling's not especially opaque guide to how to understand a novelist's life and to appreciate their work, in short, her first ‘Lake and Shed' discussion (albeit one embedded in story). He explores Kathryn Kent's blog entry about Plot and Narrative as Rowling's pointer to the syuzhet and Fabula distinction of the Russian Formalists, the key to understanding what writers do and create.New to the Lake and Shed Kanreki Birthday series? Here's what we're doing:On 31 July 2025, Joanne Murray, aka J. K. Rowling and Robert Galbraith, will be celebrating her 60th birthday. This celebration is considered a ‘second birth' in Japan or Kanreki because it is the completion of the oriental astrological cycle. To mark JKR's Kanreki, Dr John Granger and Nick Jeffery, both Nipponophiles, are reading through Rowling's twenty-one published works and reviewing them in light of the author's writing process, her ‘Lake and Shed' metaphor. The ‘Lake' is the biographical source of her inspiration; the ‘Shed' is the alocal place of her intentional artistry, in which garage she transforms the biographical stuff provided by her subconscious mind into the archetypal stories that have made her the most important author of her age. You can hear Nick and John discuss this process and their birthday project at the first entry in this series of posts: Happy Birthday, JKR! A Lake and Shed Celebration of her Life and Work.The nine HogwartsProfessor birthday videos posted thus far in this series can be read at the links below:* A Lake and Shed Reading of Harry Potter and the Philosopher's Stone* A Lake and Shed Reading of Harry Potter and the Chamber of Secrets* A Lake and Shed Reading of Harry Potter and the Prisoner of Azkaban* A Lake and Shed Reading of Harry Potter and the Goblet of Fire* A Lake and Shed Reading of Harry Potter and the Order of the Phoenix* A Lake and Shed Reading of Harry Potter and the Half-Blood Prince* A Lake and Shed Reading of Harry Potter and the Deathly Hallows* A Lake and Shed Reading of Casual Vacancy* A Lake and Shed Reading of Cuckoo's CallingTomorrow? It's Career of Evil, the Comoran Strike novel unlike all others and one which Serious Strikers either love or love to hate. Links to posts mentioned in today's Lake and Shed conversation for further reading:Does Rowling Merit the Nobel Prize in Literature?* Syuzhet and Fabula* Poeima, Genre, and Influence* LiterarinessKathryn Kent's Plot-Narrative DistinctionFirst Thoughts on The SilkwormBeatrice Groves on Early Modern Revenge Drama and The Silkworm* John's Thoughts on the Poisoned Skeleton in The Silkworm Get full access to Hogwarts Professor at hogwartsprofessor.substack.com/subscribe

Andrew Walworth, Carl Cannon and National Review contributor Heather Wilhelm discuss whether President Trump should receive The Nobel Peace Prize, and the politics behind the selection process. The they discuss former White House physician Dr. Kevin O'Connor's surprise decision to assert his Fifth Amendment rights to avoid self-incrimination during an interview with House lawmakers and California Governor Gavin Newsom's tour of South Carolina. Then Andrew Walworth and Carl Cannon talk with Miranda Devine, New York Post columnist and host of the podcast “Pod Force One,” about her recent exclusive interview with White House chief of staff Susie Wiles. Then they speak with RCP National Correspondent Susan Crabtree about the news that the Secret Service has suspended agents involved in the assassination attempt against Donald Trump last year in Butler, Pennsylvania.

Dr. Paul Hanona and Dr. Arturo Loaiza-Bonilla discuss how to safely and smartly integrate AI into the clinical workflow and tap its potential to improve patient-centered care, drug development, and access to clinical trials. TRANSCRIPT Dr. Paul Hanona: Hello, I'm Dr. Paul Hanona, your guest host of the ASCO Daily News Podcast today. I am a medical oncologist as well as a content creator @DoctorDiscover, and I'm delighted to be joined today by Dr. Arturo Loaiza-Bonilla, the chief of hematology and oncology at St. Luke's University Health Network. Dr. Bonilla is also the co-founder and chief medical officer at Massive Bio, an AI-driven platform that matches patients with clinical trials and novel therapies. Dr. Loaiza-Bonilla will share his unique perspective on the potential of artificial intelligence to advance precision oncology, especially through clinical trials and research, and other key advancements in AI that are transforming the oncology field. Our full disclosures are available in the transcript of the episode. Dr. Bonilla, it's great to be speaking with you today. Thanks for being here. Dr. Arturo Loaiza-Bonilla: Oh, thank you so much, Dr. Hanona. Paul, it's always great to have a conversation. Looking forward to a great one today. Dr. Paul Hanona: Absolutely. Let's just jump right into it. Let's talk about the way that we see AI being embedded in our clinical workflow as oncologists. What are some practical ways to use AI? Dr. Arturo Loaiza-Bonilla: To me, responsible AI integration in oncology is one of those that's focused on one principle to me, which is clinical purpose is first, instead of the algorithm or whatever technology we're going to be using. If we look at the best models in the world, they're really irrelevant unless we really solve a real day-to-day challenge, either when we're talking to patients in the clinic or in the infusion chair or making decision support. Currently, what I'm doing the most is focusing on solutions that are saving us time to be more productive and spend more time with our patients. So, for example, we're using ambient AI for appropriate documentation in real time with our patients. We're leveraging certain tools to assess for potential admission or readmission of patients who have certain conditions as well. And it's all about combining the listening of physicians like ourselves who are end users, those who create those algorithms, data scientists, and patient advocates, and even regulators, before they even write any single line of code. I felt that on my own, you know, entrepreneurial aspects, but I think it's an ethos that we should all follow. And I think that AI shouldn't be just bolted on later. We always have to look at workflows and try to look, for example, at clinical trial matching, which is something I'm very passionate about. We need to make sure that first, it's easier to access for patients, that oncologists like myself can go into the interface and be able to pull the data in real time when you really need it, and you don't get all this fatigue alerts. To me, that's the responsible way of doing so. Those are like the opportunities, right? So, the challenge is how we can make this happen in a meaningful way – we're just not reacting to like a black box suggestion or something that we have no idea why it came up to be. So, in terms of success – and I can tell you probably two stories of things that we know we're seeing successful – we all work closely with radiation oncologists, right? So, there are now these tools, for example, of automated contouring in radiation oncology, and some of these solutions were brought up in different meetings, including the last ASCO meeting. But overall, we know that transformer-based segmentation tools; transformer is just the specific architecture of the machine learning algorithm that has been able to dramatically reduce the time for colleagues to spend allotting targets for radiation oncology. So, comparing the target versus the normal tissue, which sometimes it takes many hours, now we can optimize things over 60%, sometimes even in minutes. So, this is not just responsible, but it's also an efficiency win, it's a precision win, and we're using it to adapt even mid-course in response to tumor shrinkage. Another success that I think is relevant is, for example, on the clinical trial matching side. We've been working on that and, you know, I don't want to preach to the choir here, but having the ability for us to structure data in real time using these tools, being able to extract information on biomarkers, and then show that multi-agentic AI is superior to what we call zero-shot or just throwing it into ChatGPT or any other algorithm, but using the same tools but just fine-tuned to the point that we can be very efficient and actually reliable to the level of almost like a research coordinator, is not just theory. Now, it can change lives because we can get patients enrolled in clinical trials and be activated in different places wherever the patient may be. I know it's like a long answer on that, but, you know, as we talk about responsible AI, that's important. And in terms of what keeps me up at night on this: data drift and biases, right? So, imaging protocols, all these things change, the lab switch between different vendors, or a patient has issues with new emerging data points. And health systems serve vastly different populations. So, if our models are trained in one context and deployed in another, then the output can be really inaccurate. So, the idea is to become a collaborative approach where we can use federated learning and patient-centricity so we can be much more efficient in developing those models that account for all the populations, and any retraining that is used based on data can be diverse enough that it represents all of us and we can be treated in a very good, appropriate way. So, if a clinician doesn't understand why a recommendation is made, as you probably know, you probably don't trust it, and we shouldn't expect them to. So, I think this is the next wave of the future. We need to make sure that we account for all those things. Dr. Paul Hanona: Absolutely. And even the part about the clinical trials, I want to dive a little bit more into in a few questions. I just kind of wanted to make a quick comment. Like you said, some of the prevalent things that I see are the ambient scribes. It seems like that's really taken off in the last year, and it seems like it's improving at a pretty dramatic speed as well. I wonder how quickly that'll get adopted by the majority of physicians or practitioners in general throughout the country. And you also mentioned things with AI tools regarding helping regulators move things quicker, even the radiation oncologist, helping them in their workflow with contouring and what else they might have to do. And again, the clinical trials thing will be quite interesting to get into. The first question I had subsequent to that is just more so when you have large datasets. And this pertains to two things: the paper that you published recently regarding different ways to use AI in the space of oncology referred to drug development, the way that we look at how we design drugs, specifically anticancer drugs, is pretty cumbersome. The steps that you have to take to design something, to make sure that one chemical will fit into the right chemical or the structure of the molecule, that takes a lot of time to tinker with. What are your thoughts on AI tools to help accelerate drug development? Dr. Arturo Loaiza-Bonilla: Yes, that's the Holy Grail and something that I feel we should dedicate as much time and effort as possible because it relies on multimodality. It cannot be solved by just looking at patient histories. It cannot be solved by just looking at the tissue alone. It's combining all these different datasets and being able to understand the microenvironment, the patient condition and prior treatments, and how dynamic changes that we do through interventions and also exposome – the things that happen outside of the patient's own control – can be leveraged to determine like what's the best next step in terms of drugs. So, the ones that we heard the news the most is, for example, the Nobel Prize-winning [for Chemistry awarded to Demis Hassabis and John Jumper for] AlphaFold, an AI system that predicts protein structures right? So, we solved this very interesting concept of protein folding where, in the past, it would take the history of the known universe, basically – what's called the Levinthal's paradox – to be able to just predict on amino acid structure alone or the sequence alone, the way that three-dimensionally the proteins will fold. So, with that problem being solved and the Nobel Prize being won, the next step is, “Okay, now we know how this protein is there and just by sequence, how can we really understand any new drug that can be used as a candidate and leverage all the data that has been done for many years of testing against a specific protein or a specific gene or knockouts and what not?” So, this is the future of oncology and where we're probably seeing a lot of investments on that. The key challenge here is mostly working on the side of not just looking at pathology, but leveraging this digital pathology with whole slide imaging and identifying the microenvironment of that specific tissue. There's a number of efforts currently being done. One isn't just H&E, like hematoxylin and eosin, slides alone, but with whole imaging, now we can use expression profiles, spatial transcriptomics, and gene whole exome sequencing in the same space and use this transformer technology in a multimodality approach that we know already the slide or the pathology, but can we use that to understand, like, if I knock out this gene, how is the microenvironment going to change to see if an immunotherapy may work better, right? If we can make a microenvironment more reactive towards a cytotoxic T cell profile, for example. So, that is the way where we're really seeing the field moving forward, using multimodality for drug discovery. So, the FDA now seems to be very eager to support those initiatives, so that's of course welcome. And now the key thing is the investment to do this in a meaningful way so we can see those candidates that we're seeing from different companies now being leveraged for rare disease, for things that are going to be almost impossible to collect enough data, and make it efficient by using these algorithms that sometimes, just with multiple masking – basically, what they do is they mask all the features and force the algorithm to find solutions based on the specific inputs or prompts we're doing. So, I'm very excited about that, and I think we're going to be seeing that in the future. Dr. Paul Hanona: So, essentially, in a nutshell, we're saying we have the cancer, which is maybe a dandelion in a field of grass, and we want to see the grass that's surrounding the dandelion, which is the pathology slides. The problem is, to the human eye, it's almost impossible to look at every single piece of grass that's surrounding the dandelion. And so, with tools like AI, we can greatly accelerate our study of the microenvironment or the grass that's surrounding the dandelion and better tailor therapy, come up with therapy. Otherwise, like you said, to truly generate a drug, this would take years and years. We just don't have the throughput to get to answers like that unless we have something like AI to help us. Dr. Arturo Loaiza-Bonilla: Correct. Dr. Paul Hanona: And then, clinical trials. Now, this is an interesting conversation because if you ever look up our national guidelines as oncologists, there's always a mention of, if treatment fails, consider clinical trials. Or in the really aggressive cancers, sometimes you might just start out with clinical trials. You don't even give the standard first-line therapy because of how ineffective it is. There are a few issues with clinical trials that people might not be aware of, but the fact that the majority of patients who should be on clinical trials are never given the chance to be on clinical trials, whether that's because of proximity, right, they might live somewhere that's far from the institution, or for whatever reason, they don't qualify for the clinical trial, they don't meet the strict inclusion criteria.  But a reason you mentioned early on is that it's simply impossible for someone to be aware of every single clinical trial that's out there. And then even if you are aware of those clinical trials, to actually find the sites and put in the time could take hours. And so, how is AI going to revolutionize that? Because in my mind, it's not that we're inventing a new tool. Clinical trials have always been available. We just can't access them. So, if we have a tool that helps with access, wouldn't that be huge? Dr. Arturo Loaiza-Bonilla: Correct. And that has been one of my passions. And for those who know me and follow me and we've spoke about it in different settings, that's something that I think we can solve. This other paradox, which is the clinical trial enrollment paradox, right? We have tens of thousands of clinical trials available with millions of patients eager to learn about trials, but we don't enroll enough and many trials close to accrual because of lack of enrollment. It is completely paradoxical and it's because of that misalignment because patients don't know where to go for trials and sites don't know what patients they can help because they haven't reached their doors yet. So, the solution has to be patient-centric, right? We have to put the patient at the center of the equation. And that was precisely what we had been discussing during the ASCO meeting. There was an ASCO Education Session where we talked about digital prescreening hubs, where we, in a patient-centric manner, the same way we look for Uber, Instacart, any solution that you may think of that you want something that can be leveraged in real time, we can use these real-world data streams from the patient directly, from hospitals, from pathology labs, from genomics companies, to continuously screen patients who can match to the inclusion/exclusion criteria of unique trials. So, when the patient walks into the clinic, the system already knows if there's a trial and alerts the site proactively. The patient can actually also do decentralization. So, there's a number of decentralized clinical trial solutions that are using what I call the “click and mortar” approach, which is basically the patient is checking digitally and then goes to the site to activate. We can also have the click and mortar in the bidirectional way where the patient is engaged in person and then you give the solution like the ones that are being offered on things that we're doing at Massive Bio and beyond, which is having the patient to access all that information and then they make decisions and enroll when the time is right.  As I mentioned earlier, there is this concept drift where clinical trials open and close, the patient line of therapy changes, new approvals come in and out, and sites may not be available at a given time but may be later. So, having that real-time alerts using tools that are able already to extract data from summarization that we already have in different settings and doing this natural language ingestion, we can not only solve this issue with manual chart review, which is extremely cumbersome and takes forever and takes to a lot of one-time assessments with very high screen failures, to a real-time dynamic approach where the patient, as they get closer to that eligibility criteria, they get engaged. And those tools can be built to activate trials, audit trials, and make them better and accessible to patients. And something that we know is, for example, 91%-plus of Americans live close to either a pharmacy or an imaging center. So, imagine that we can potentially activate certain of those trials in those locations. So, there's a number of pharmacies, special pharmacies, Walgreens, and sometimes CVS trying to do some of those efforts. So, I think the sky's the limit in terms of us working together. And we've been talking with corporate groups, they're all interested in those efforts as well, to getting patients digitally enabled and then activate the same way we activate the NCTN network of the corporate groups, that are almost just-in-time. You can activate a trial the patient is eligible for and we get all these breakthroughs from the NIH and NCI, just activate it in my site within a week or so, as long as we have the understanding of the protocol. So, using clinical trial matching in a digitally enabled way and then activate in that same fashion, but not only for NCTN studies, but all the studies that we have available will be the key of the future through those prescreening hubs. So, I think now we're at this very important time where collaboration is the important part and having this silo-breaking approach with interoperability where we can leverage data from any data source and from any electronic medical records and whatnot is going to be essential for us to move forward because now we have the tools to do so with our phones, with our interests, and with the multiple clinical trials that are coming into the pipelines. Dr. Paul Hanona: I just want to point out that the way you described the process involves several variables that practitioners often don't think about. We don't realize the 15 steps that are happening in the background. But just as a clarifier, how much time is it taking now to get one patient enrolled on a clinical trial? Is it on the order of maybe 5 to 10 hours for one patient by the time the manual chart review happens, by the time the matching happens, the calls go out, the sign-up, all this? And how much time do you think a tool that could match those trials quicker and get you enrolled quicker could save? Would it be maybe an hour instead of 15 hours? What's your thought process on that? Dr. Arturo Loaiza-Bonilla: Yeah, exactly. So one is the matching, the other one is the enrollment, which, as you mentioned, is very important. So, it can take, from, as you said, probably between 4 days to sometimes 30 days. Sometimes that's how long it takes for all the things to be parsed out in terms of logistics and things that could be done now agentically. So, we can use agents to solve those different steps that may take multiple individuals. We can just do it as a supply chain approach where all those different steps can be done by a single agent in a simultaneous fashion and then we can get things much faster. With an AI-based solution using these frontier models and multi-agentic AI – and we presented some of this data in ASCO as well – you can do 5,000 patients in an hour, right? So, just enrolling is going to be between an hour and maximum enrollment, it could be 7 days for those 5,000 patients if it was done at scale in a multi-level approach where we have all the trials available. Dr. Paul Hanona: No, definitely a very exciting aspect of our future as oncologists. It's one thing to have really neat, novel mechanisms of treatment, but what good is it if we can't actually get it to people who need it? I'm very much looking for the future of that.  One of the last questions I want to ask you is another prevalent way that people use AI is just simply looking up questions, right? So, traditionally, the workflow for oncologists is maybe going on national guidelines and looking up the stage of the cancer and seeing what treatments are available and then referencing the papers and looking at who was included, who wasn't included, the side effects to be aware of, and sort of coming up with a decision as to how to treat a cancer patient. But now, just in the last few years, we've had several tools become available that make getting questions easier, make getting answers easier, whether that's something like OpenAI's tools or Perplexity or Doximity or OpenEvidence or even ASCO has a Guidelines Assistant as well that is drawing from their own guidelines as to how to treat different cancers. Do you see these replacing traditional sources? Do you see them saving us a lot more time so that we can be more productive in clinic? What do you think is the role that they're going to play with patient care? Dr. Arturo Loaiza-Bonilla: Such a relevant question, particularly at this time, because these AI-enabled query tools, they're coming left and right and becoming increasingly common in our daily workflows and things that we're doing. So, traditionally, when we go and we look for national guidelines, we try to understand the context ourselves and then we make treatment decisions accordingly. But that is a lot of a process that now AI is helping us to solve. So, at face value, it seems like an efficiency win, but in many cases, I personally evaluate platforms as the chief of hem/onc at St. Luke's and also having led the digital engagement things through Massive Bio and trying to put things together, I can tell you this: not all tools are created equal. In cancer care, each data point can mean the difference between cure and progression, so we cannot really take a lot of shortcuts in this case or have unverified output. So, the tools are helpful, but it has to be grounded in truth, in trusted data sources, and they need to be continuously updated with, like, ASCO and NCCN and others. So, the reason why the ASCO Guidelines Assistant, for instance, works is because it builds on all these recommendations, is assessed by end users like ourselves. So, that kind of verification is critical, right? We're entering a phase where even the source material may be AI-generated. So, the role of human expert validation is really actually more important, not less important. You know, generalist LLMs, even when fine-tuned, they may not be enough. You can pull a few API calls from PubMed, etc., but what we need now is specialized, context-aware, agentic tools that can interpret multimodal and real-time clinical inputs. So, something that we are continuing to check on and very relevant to have entities and bodies like ASCO looking into this so they can help us to be really efficient and really help our patients. Dr. Paul Hanona: Dr. Bonilla, what do you want to leave the listener with in terms of the future direction of AI, things that we should be cautious about, and things that we should be optimistic about? Dr. Arturo Loaiza-Bonilla: Looking 5 years ahead, I think there's enormous promise. As you know, I'm an AI enthusiast, but always, there's a few priorities that I think – 3 of them, I think – we need to tackle head-on. First is algorithmic equity. So, most AI tools today are trained on data from academic medical centers but not necessarily from community practices or underrepresented populations, particularly when you're looking at radiology, pathology, and what not. So, those blind spots, they need to be filled, and we can eliminate a lot of disparities in cancer care. So, those frameworks to incentivize while keeping the data sharing using federated models and things that we can optimize is key. The second one is the governance on the lifecycle. So, you know, AI is not really static. So, unlike a drug that is approved and it just, you know, works always, AI changes. So, we need to make sure that we have tools that are able to retrain and recall when things degrade or models drift. So, we need to use up-to-date AI for clinical practice, so we are going to be in constant revalidation and make it really easy to do. And lastly, the human-AI interface. You know, clinicians don't need more noise or we don't need more black boxes. We need decision support that is clear, that we can interpret, and that is actionable. “Why are you using this? Why did we choose this drug? Why this dose? Why now?” So, all these things are going to help us and that allows us to trace evidence with a single click. So, I always call it back to the Moravec's paradox where we say, you know, evolution gave us so much energy to discern in the sensory-neural and dexterity. That's what we're going to be taking care of patients. We can use AI to really be a force to help us to be better clinicians and not to really replace us. So, if we get this right and we decide for transparency with trust, inclusion, etc., it will never replace any of our work, which is so important, as much as we want, we can actually take care of patients and be personalized, timely, and equitable. So, all those things are what get me excited every single day about these conversations on AI. Dr. Paul Hanona: All great thoughts, Dr. Bonilla. I'm very excited to see how this field evolves. I'm excited to see how oncologists really come to this field. I think with technology, there's always a bit of a lag in adopting it, but I think if we jump on board and grow with it, we can do amazing things for the field of oncology in general. Thank you for the advancements that you've made in your own career in the field of AI and oncology and just ultimately with the hopeful outcomes of improving patient care, especially cancer patients. Dr. Arturo Loaiza-Bonilla: Thank you so much, Dr. Hanona. Dr. Paul Hanona: Thanks to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Arturo Loaiza-Bonilla @DrBonillaOnc Dr. Paul Hanona @DoctorDiscover on YouTube Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn    ASCO on BlueSky Disclosures: Paul Hanona: No relationships to disclose. Dr. Arturo-Loaiza-Bonilla: Leadership: Massive Bio Stock & Other Ownership Interests: Massive Bio Consulting or Advisory Role: Massive Bio, Bayer, PSI, BrightInsight, CardinalHealth, Pfizer, AstraZeneca, Medscape Speakers' Bureau: Guardant Health, Ipsen, AstraZeneca/Daiichi Sankyo, Natera

In this conversation, Tricia Friedman and Homa Tavangar explore the significance of asking big questions in leadership, the importance of relationships, and the need for deeper connections in education and community. They discuss how embracing complexity and uncertainty can lead to growth, the role of play in learning, and the necessity of listening to unheard voices. The dialogue also touches on redefining leadership to combat loneliness and the importance of cultivating awe and spirituality in our lives. Meet our guest: Homa Tavangar is the co-founder of the Big Questions Institute and the Oneness Lab. She brings 30+ years' experience helping diverse organizations and individuals to build cultural, racial and global competence, strategic governance, and visionary, generative leadership in diverse schools and organizations. She coaches leaders on accountability for equity, leading through crisis, and advises on strategic design and planning across five continents. She has co-authored seven books for educators, and is the author of best-selling Growing Up Global: Raising Children to Be At Home in the World (published by Random House) and Global Kids (Barefoot Books). Her most recent publication is 12 Big Questions Schools Must Answer to Create Irresistible Futures with Will Richardson (forthcoming, 2025). A graduate of UCLA and Princeton, Homa was born in Iran, has lived on four continents, speaks four languages, and has heritage in four world religions. She serves on several Boards, including ISS (International Schools Services) and is a judge for the Templeton Prize, considered the “world's most interesting prize” with a purse calibrated to exceed the Nobel Prize. She is married and the mother of three adult daughters, and resides in Villanova, Pennsylvania. https://homatavangar.com/about-homa Chapters 00:00 The Power of Questions in Leadership 04:06 Embracing Relationships as Solutions 09:46 Nature and Relational Intelligence 18:31 The Role of Boards in Education 23:50 Reframing Leadership as an Act of Love 29:52 The Role of Joy in Education 31:50 Social Emotional Learning: A Double-Edged Sword 34:20 Loneliness in Leadership and the Need for Connection 36:13 Global Citizenship: Friendship and Community 41:27 Seeking Spiritual Guidance in Education 44:28 Cultivating Awe and Community Connections

“I've never been part of the gang. I was a one-man band playing little tunes.” – Meet physics laureate John Hopfield in a podcast recorded at his cottage in Selborne, England. Together with host Adam Smith, he reflects on the value of interdisciplinary work and how chemists and physicists might collaborate more closely. They also discuss the future of AI and Hopfield's greatest fears about it. Hosted on Acast. See acast.com/privacy for more information.

In the sixth of this six-part series of The Economics Show, Martin Wolf, the FT's chief economics commentator, and Nobel Prize-winning economist Paul Krugman tackle a selection of questions, and even some criticisms, sent in by their audience. Listen to Paul Krugman's cultural coda, Carole King's It's too late, here Listen to Martin Wolf's cultural coda, Va Pensiero from Verdi's Nabucco, hereSubscribe and listen to this series on The Economics Show on Apple Podcasts, Spotify, Pocket Casts or wherever you listen to podcasts. Episodes are also available on the FT's YouTube channel.Read Martin's FT column hereSubscribe to Paul's substack hereThe Wolf-Krugman Exchange was produced by Sandra Kanthal and Mischa Frankl-Duval, and the broadcast engineer was Andrew Georgiades. The sound engineer was Breen Turner. Manuela Saragosa is the FT's acting co-head of audio.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

-- On the Show: -- David hosts a Substack Live with Brian Tyler Cohen -- Trump deploys militarized federal forces to MacArthur Park in Los Angeles in a chilling test run of authoritarian power projection -- Karoline Leavitt embarrassingly backpedals on the Epstein list, exposing a key MAGA lie and deepening Trump's credibility crisis -- Trump's team can't explain what happened to the long-promised Epstein client list, casting doubt on years of MAGA conspiracy claims -- Trump's press secretary spirals on live TV, failing to defend collapsing trade deals, flood response failures, and a phantom Epstein list -- Trump delays his tariff threat again, proving once more that his “tough” trade stance is all bluff and political cowardice -- Trump floods world leaders with unhinged tariff letters, creating global confusion and economic anxiety -- Trump rambles incoherently at a White House dinner, praising dictators, flip-flopping on trade, and exposing chaos behind his Ukraine and tariff policies -- Benjamin Netanyahu flatters Trump with a fake Nobel Prize nomination and Trump falls for it completely, clueless he's being manipulated -- On the Bonus Show: Ted Cruz vacations again during Texas natural disaster, inhumane conditions reported at Alligator Alcatraz, IRS says churches can endorse candidates, and much more... ⚠️ Ground News: Get 40% OFF their unlimited access Vantage plan at https://ground.news/pakman

07-08-25 - Entertainment Drill - TUE - Trump Admin Says There Is No Epstein List And Israel Puts Trump Up For Nobel PrizeSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to The Times of Israel's Daily Briefing, your 20-minute audio update on what's happening in Israel, the Middle East and the Jewish world. Diplomatic correspondent Lazar Berman and US bureau chief Jacob Magid join host Amanda Borschel-Dan for today's episode. Israeli Prime Minister Benjamin Netanyahu is in Washington, DC, but mediators in the ongoing negotiations for a Gaza ceasefire and hostage release deal have been notified by the Trump administration that the president expects them to secure an agreement this week. US Special Envoy to the Mideast Steve Witkoff will travel to Doha today to advance the deal. We hear from Magid and Berman what the atmosphere is like in DC: Are officials still hopeful a deal could occur according to Trump's timeline? Ahead of a White House dinner, both US President Donald Trump and Netanyahu took American media's questions, including a query about the viability of the two-state solution. We learn what Netanyahu said at the dinner, as well as remarks following the meal from a senior Israeli official who intimated that Israel is ready to temporarily govern the Gaza Strip: “There has to be a system there that manages life,” the official said. “Maybe for a certain amount of time, it is us." Yesterday, the US announced that it was revoking its “foreign terrorist organization” designation of Hayat Tahrir al-Sham (HTS), the group once linked to Al-Qaeda that took control of Syria in December 2024. This comes after last week, Trump formally dismantled US sanctions against Syria. We learn what was said during the Trump-Netanyahu dinner and the US's hopes to reintegrate Syria into the global economy. Part of the reason that Netanyahu is in DC is to celebrate the success of the 12-day Israel-Iran war. In a briefing with a senior Israeli official following the dinner, it was also noted that Israel anticipates the US will permit it to launch new strikes on Iran, in the event that the Islamic Republic attempts to restart its nuclear program. There was no ceasefire deal announcement, but there was drama of a different sort: Following Trump’s opening remarks to reporters before their White House dinner, Netanyahu expressed his appreciation for the American leader on behalf of Israelis as well as Jews around the world and presented Trump with a letter he sent to the Nobel Prize committee nominating the US president for the peace prize. Check out The Times of Israel's ongoing liveblog for more updates. For further reading: 5 IDF soldiers killed, 14 injured by roadside bomb in northern Gaza Witkoff to join hostage talks in Doha Tuesday as sides told Trump wants deal by week’s end Katz calls for confining all Gazans in ‘humanitarian city’ built over Rafah’s ruins US revokes terror label for Syria’s Hayat Tahrir al-Sham, which toppled Assad Proposal outlines massive camps for Gazans in bid to advance Trump’s ‘vision’ – report Israel said to expect US backing for future strikes on Iran if it revives nuclear program Netanyahu surprises Trump with Nobel recommendation, as leaders stress coordination Subscribe to The Times of Israel Daily Briefing on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. This episode was produced by the Pod-Waves. IMAGE: A Palestinian tent city in the Al-Mawasi area in Khan Yunis, southern Gaza Strip, July 6, 2025. (Abed Rahim Khatib/Flash90)See omnystudio.com/listener for privacy information.

Today on Rising, Robby Soave delivers radar in the top three most progressive -- Zohran Mamdani, Rep. Alexandria Ocasio-Cortez and Sen. Bernie Sanders -- leading the Democratic Party. British TV host Piers Morgan and journalist Owen Jones argue over the Oct. 7, 2023. attack on Israel. Meanwhile. White House Press Secretary Karoline Leavitt gets grilled on Estein files. Airplane travelers will no longer have to take off their shoes in security checkpoints, the TSA announces. Tucker Carlson scores interview with Iranian president. Actor Mark Ruffalo unleashes on Joe Rogan. This, and more. #Rising Learn more about your ad choices. Visit megaphone.fm/adchoices

07-08-25 - Entertainment Drill - TUE - Trump Admin Says There Is No Epstein List And Israel Puts Trump Up For Nobel PrizeSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Eric Topol (00:05):Hello, it's Eric Topol from Ground Truths, and I've got some really exciting stuff to talk to you about today. And it's about the announcement for a new Center for pediatric CRISPR Cures. And I'm delight to introduce doctors Jennifer Doudna and Priscilla Chan. And so, first let me say this is amazing to see this thing going forward. It's an outgrowth of a New England Journal paper and monumental report on CRISPR in May. [See the below post for more context]Let me introduce first, Dr. Doudna. Jennifer is the Li Ka Shing Chancellor's Chair and a Professor in the departments of chemistry and of molecular and cell biology at the University of California Berkeley. She's also the subject of this book, one of my favorite books of all time, the Code Breaker. And as you know, the 2020 Nobel Prize laureate for her work in CRISPR-Cas9 genome editing, and she founded the Innovative Genomics Institute (IGI) back 10 years ago. So Jennifer, welcome.Jennifer Doudna (01:08):Thank you, Eric. Great to be here.Eric Topol (01:10):And now Dr. Priscilla Chan, who is the co-founder of the Chan Zuckerberg Initiative (CZI) that also was started back in 2015. So here we are, a decade later, these two leaders. She is a pediatrician having trained at UCSF and is committed to the initiative which has as its mission statement, “to make it possible to cure, prevent, and manage all diseases in this century.” So today we're going to talk about a step closer to that. Welcome, Priscilla.Priscilla Chan (01:44):Thank you. Thanks for having me.Eric Topol (01:46):Alright, so I thought we'd start off by, how did you two get together? Have you known each other for over this past decade since you both got all your things going?Jennifer Doudna (01:56):Yes, we have. We've known each other for a while. And of course, I've admired the progress at the CZI on fundamental science. I was an advisor very early on and I think actually that's how we got to know each other. Right, Priscilla?Priscilla Chan (02:11):Yeah, that's right. We got to know each other then. And we've been crisscrossing paths. And I personally remember the day you won the Nobel Prize. It was in the heart of the pandemic and a lot of celebrations were happening over Zoom. And I grabbed my then 5-year-old and got onto the UCSF celebration and I was like, look, this is happening. And it was really cool for me and for my daughter.Eric Topol (02:46):Well, it's pretty remarkable convergence leading up to today's announcement, but I know Priscilla, that you've been active in this rare disease space, you've had at CZI a Rare As One Project. Maybe you could tell us a bit about that.Priscilla Chan (03:01):Yeah, so at CZI, we work on basic science research, and I think that often surprises people because they know that I'm a pediatrician. And so, they often think, oh, you must work in healthcare or healthcare delivery. And we've actually chosen very intentionally to work in basic science research. In part because my training as a pediatrician at UCSF. As you both know, UCSF is a tertiary coronary care center where we see very unusual and rare cases of pediatric presentations. And it was there where I learned how little we knew about rare diseases and diseases in general and how powerful patients were. And that research was the pipeline for hope and for new discoveries for these families that often otherwise don't have very much access to treatments or cures. They have a PDF that maybe describes what their child has. And so, I decided to invest in basic science through CZI, but always saw the power of bringing rare disease patient cohorts. One, because if you've ever met a parent of a child with rare disease, they are a force to be reckoned with. Two, they can make research so much better due to their insights as patients and patient advocates. And I think they close the distance between basic science and impact in patients. And so, we've been working on that since 2019 and has been a passion of ours.Eric Topol (04:40):Wow, that's great. Now Jennifer, this IGI that you founded a decade ago, it's doing all kinds of things that are even well beyond rare diseases. We recently spoke, I know on Ground Truths about things as diverse as editing the gut microbiome in asthma and potentially someday Alzheimer's. But here you were very much involved at IGI with the baby KJ Muldoon. Maybe you could take us through this because this is such an extraordinary advance in the whole CRISPR Cures story.Jennifer Doudna (05:18):Yes, Eric. It's a very exciting story and we're very, very proud of the teamwork that went into making it possible to cure baby KJ of his very rare disease. And in brief, the story began back in August of last year when he was born with a metabolic disorder that prevented him from digesting protein, it's called a urea cycle disorder and rare, but extremely severe. And to the point where he was in the ICU and facing a very, very difficult prognosis. And so, fortunately his clinical team at Children's Hospital of Philadelphia (CHOP) reached out to Fyodor Urnov, who is the Director of Translational Medicine at the IGI here in the Bay Area. They teamed up and realized that they could quickly diagnose that child because we had an IRB approved here at the IGI that allowed us to collect patient samples and do diagnosis. So that was done.Jennifer Doudna (06:26):We created an off-the-shelf CRISPR therapy that would be targeted to the exact mutation that caused that young boy's disease. And then we worked with the FDA in Washington to make sure that we could very safely proceed with testing of that therapy initially in the lab and then ultimately in two different animal models. And then we opened a clinical trial that allowed that boy to be enrolled with, of course his parents' approval and for him to be dosed and the result was spectacular. And in fact, he was released from the hospital recently as a happy, healthy child, gaining lots of weight and looking very chunky. So it's really exciting.Eric Topol (07:16):It's so amazing. I don't think people necessarily grasp this. This timeline [see above] that we'll post with this is just mind boggling how you could, as you said Jennifer, in about six months to go from the birth and sequencing through cell specific cultures with the genome mutations through multiple experimental models with non-human primates even, looking at off-target effects, through the multiple FDA reviews and then dosing, cumulatively three dosing to save this baby's life. It really just amazing. Now that is a template. And before we go to this new Center, I just wanted to also mention not just the timeline of compression, which is unimaginable and the partnership that you've had at IGI with I guess Danaher to help manufacture, which is just another part of the story. But also the fact that you're not just even with CRISPR 1.0 as being used in approvals previously for sickle cell and β-thalassemia, but now we're talking about base editing in vivo in the body using mRNA delivery. So maybe you could comment on that, Jennifer.Jennifer Doudna (08:38):Yeah, very good point. So yeah, we used a version of CRISPR that was created by David Liu at the Broad Institute and published and available. And so, it was possible to create that, again, targeted to the exact mutation that caused baby KJ's disease. And fortunately, there was also an off-the-shelf way to deliver it because we had access to lipid nanoparticles that were developed for other purposes including vaccinations. And the type of disease that KJ suffered from is one that is treatable by editing cells in the liver, which is where the lipid nanoparticle naturally goes. So there were definitely some serendipity here, but it was amazing how all of these pieces were available. We just had to pull them together to create this therapy.Eric Topol (09:30):Yeah, no, it is amazing. So that I think is a great substrate for starting a new Center. And so, maybe back to you Priscilla, as to what your vision was when working with Jennifer and IGI to go through with this.Priscilla Chan (09:45):I think the thing that's incredibly exciting, you mentioned that at CZI our mission is to cure, prevent, and manage all disease. And when we talked about this 10 years ago, it felt like this far off idea, but every day it seems closer and closer. And I think the part that's super exciting about this is the direct connection between the basic science that's happening in CRISPR and the molecular and down to the nucleotide understanding of these mutations and the ability to correct them. And I think many of us, our imaginations have included this possibility, but it's very exciting that it has happened with baby KJ and CHOP. And we need to be able to do the work to understand how we can treat more patients this way, how to understand the obstacles, unblock them, streamline the process, bring down the cost, so that we better understand this pathway for treatment, as well as to increasingly democratize access to this type of platform. And so, our hope is to be able to do that. Take the work and inspiration that IGI and the team at CHOP have done and continue to push forward and to look at more cases, look at more organ systems. We're going to be looking in addition to the liver, at the bone marrow and the immune system.Priscilla Chan (11:17):And to be able to really work through more of the steps so that we can bring this to more families and patients.Eric Topol (11:30):Yeah, well it's pretty remarkable because here you have incurable ultra-rare diseases. If you can help these babies, just think of what this could do in a much broader context. I mean there a lot of common diseases have their roots with some of these very rare ones. So how do you see going forward, Jennifer, as to where you UC Berkeley, Gladstone, UCSF. I'm envious of you all up there in Northern California I have to say, will pull this off. How will you get the first similar case to KJ Muldoon going forward?Jennifer Doudna (12:13):Right. Well, IGI is a joint institute, as you probably know, Eric. So we were founded 10 years ago as a joint institute between UC Berkeley and UCSF. And now we have a third campus partner, UC Davis and we have the Gladstone Institute. So we've got an extraordinary group of clinicians and researchers that are coming together for this project and the Center to make it a success. We are building a clinical team at UCSF. We have several extraordinary leaders including Jennifer Puck and Chris Dvorak, and they are both going to be involved in identifying patients that could be enrolled in this program based on their diagnosis. And we will have a clinical advisory group that will help with that as well. So we'll be vetting patients probably right after we announce this, we're going to be looking to start enrolling people who might need this type of help.Eric Topol (13:18):Do you think it's possible to go any faster right now than the six months that it took for KJ?Jennifer Doudna (13:26):I think it could be. And here's the reason. There's a very interesting possibility that because of the type of technology that we're talking about with CRISPR, which fundamentally, and you and I have talked about this previously on your other podcast. But we've talked about the fact that it's a programmable technology and that means that we can change one aspect of it, one piece of it, which is a piece of a molecule called RNA that's able to direct CRISPR to the right sequence where we want to do editing and not change anything else about it. The protein, the CRISPR protein stays the same, the delivery vehicle stays the same, everything else stays the same. And so, we're working right now with FDA to get a platform designation for CRISPR that might allow streamlining of the testing process in some cases. So it'll obviously come down to the details of the disease, but we're hopeful that in the end it will be possible. And Priscilla and I have talked about this too, that as AI continues to advance and we get more and more information about rare diseases, we'll be able to predict accurately the effects of editing. And so, in some cases in the future it may be possible to streamline the testing process even further safely.Eric Topol (14:51):And I also would note, as you both know, well this administration is really keen on genome editing and they've had a joint announcement regarding their support. And in my discussions with the FDA commissioner, this is something they are very excited about. So the timing of the new Center for pediatric CRISPR Cures is aligned with the current administration, which is good to see. It's not always the case. Now going back, Priscilla, to your point that not just for the liver because delivery has been an issue of course, and we're going to try to get after a lot of these really rare diseases, it's going to go beyond there. So this is also an exciting new dimension of the Center, as you said, to go after the bone marrow for hematopoietic cells, perhaps other organs as well.Priscilla Chan (15:42):I mean what the expertise and feasibility, the immune system is going to be the next target. Jennifer Puck has been a pioneer in this work. She's the one who designed the newborn screen that will be the tool that picks up these patients as they are born. And I think the thing that's tremendous is the immune system, first of all is active in many, many diseases, not just these cases of children born with partial or absence of immune systems. And the course right now that these babies are left with is complete isolation and then a very long and arduous course of a bone marrow transplant with high morbidity and mortality. And even if after the transplant you have complications like graft versus host and immunosuppression. And so, the idea of being able to very specifically and with less the conditioning and morbidity and mortality of the treatment, being able to address this is incredible. And the implications for other diseases like blood cancers or other hematopoietic diseases, that's incredible. And that actually has an incredibly broad base of patients that can benefit from the learnings from these babies with severe combined immunodeficiencies.Eric Topol (17:10):Yeah, I think that goes back to a point earlier maybe to amplify in that previous CRISPR generation, it required outside the body work and it was extremely laborious and time consuming and obviously added much more to the expense because of hospitalization time. This is different. This is basically doing this inside the affected patient's body. And that is one of the biggest reasons why this is a big step forward and why we're so fortunate that your Center is moving forward. Maybe before we wrap up, you might want to comment, Jennifer on how you were able to bring in to build this platform, the manufacturing arm of it, because that seems to be yet another dimension that's helpful.Jennifer Doudna (18:01):Indeed, yes. And we were again fortunate with timing because you mentioned briefly that the IGI had set up a program with the Danaher Corporation back in January of last year. We call it our Beacon project. And it's focused on rare disease. And it's a really interesting kind of a unique partnership because Danaher is a manufacturing conglomerate. So they have companies that make molecules, they make proteins, they make RNA molecules, they make delivery molecules. And so, they were excited to be involved with us because they want to be a provider of these types of therapies in the future. And they can see the future of CRISPR is very exciting. It's expanding, growing area. And so, that agreement was in place already when the baby KJ case came to our attention. And so, what we're hoping to do with Danaher is again, work with them and their scientists to continue to ask, how can we reduce the cost of these therapies by reducing the cost of the molecules that are necessary, how to make them efficiently. We already, it's very interesting, Fyodor Urnov has toured their plant in North Dakota recently, and he found in talking to their engineers, there are a number of things that we can already see will be possible to do that are going to make the process of manufacturing these molecules faster and cheaper by a lot.Eric Topol (19:28):Wow.Jennifer Doudna (19:28):So it's a win-win for everybody. And so, we're really excited to do that in the context of this new Center.Eric Topol (19:36):Oh, that's phenomenal because some of these disorders you don't have that much time to work with before they could be brain or organ or vital tissue damage. So that's great to hear that. What you built here is the significance of it can't be under emphasized, I'll say because we have this May report of baby KJ, which could have been a one-off and it could have been years before we saw another cure of an ultra-rare disorder. And what you're doing here is insurance against that. You're going to have many more cracks at this. And I think this is the excitement about having a new dedicated Center. So just in closing, maybe some remarks from you Priscilla.Priscilla Chan (20:24):I just want to emphasize one point that's really exciting as we talk about these ultra-rare cases that they're often like one in a million. All these learnings actually help maximize the impact of lots of research across the sector that impacts actually everyone's health. And so, our learnings here from these patients that have very significant presentations that really can stand to benefit from any treatment is hopefully paving the way for many, many more of us to be able to live healthier, higher quality lives through basic science.Eric Topol (21:13):And over to you, Jennifer.Jennifer Doudna (21:15):Couldn't agree more. It's a really interesting moment. I think what we hope we are, is we're at sort of an inflection point where, as I mentioned earlier, all the pieces are in place to do this kind of therapeutic and we just need a team that will focus on doing it and pulling it together. And also learning from that process so that as Priscilla just said, we are ultimately able to use the same strategy for other diseases and potentially for diseases that affect lots of people. So it's exciting.Eric Topol (21:46):For sure. Now, if I could just sum up, this is now a decade past the origination of your work of CRISPR and how already at the first decade culminated in sickle cell disease treatment and β-thalassemia. Now we're into the second decade of CRISPR. And look what we've seen, something that was unimaginable until it actually happened and was reported just a little over a month ago. Now going back to Priscilla's point, we're talking about thousands of different rare Mendelian genomic disorders, thousands of them. And if you add them all up of rare diseases, we're talking about hundreds of millions of people affected around the world. So this is a foray into something much bigger, no less the fact that some of these rare mutations are shared by common diseases and approaches. So this really big stuff, congratulations to both of you and your organizations, the Innovative Genomics Institute and the Chan Zuckerberg Initiative for taking this on. We'll be following it with very deep interest, thank you.****************************************************Thanks for listening, reading and subscribing to Ground Truths.If you found this interesting PLEASE share it!That makes the work involved in putting these together especially worthwhile.Thanks to Scripps Research, and my producer, Jessica Nguyen, and Sinjun Balabanoff for video/audio support.All content on Ground Truths—its newsletters, analyses, and podcasts, are free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. Get full access to Ground Truths at erictopol.substack.com/subscribe

In our first hour this Tuesday, we tell you "Five Things" that you need to know to start your morning, and we contemplate President Trump's odds of winning a Nobel Prize, following Benjamin Netanyahu's submission of a nomination to the committee.

Joseph Stiglitz is a world-renowned economist and thinker who was awarded the Nobel Prize in Economic Sciences in 2001. I met him in Tbilisi, the capital of Georgia, in June 2025 during the inspiring Zeg Festival in which we both participated. In this podcast episode, we spoke about his latest book, "The Road to Freedom", published last year, and about how flawed ideas of freedom can ultimately undermine freedom itself. I also asked him what the world can do to stop Russia's brutal invasion of Ukraine. *** Host: Volodymyr Yermolenko, a Ukrainian philosopher, the chief editor of UkraineWorld, and the president of PEN Ukraine. UkraineWorld is an English-language media outlet focusing on Ukraine and its connections with the wider world. This media outlet is run by Internews Ukraine. This episode is also made in partnership with "Politeia", a Ukrainian NGO focusing on preparing a new generation of change-makers in Ukraine. *** You can support UkraineWorld on Patreon (https://www.patreon.com/c/ukraineworld). Your support is vital, as we rely heavily on crowdfunding. You can also contribute to our volunteer missions to frontline areas in Ukraine, where we provide aid to both soldiers and civilians. Donations are welcome via PayPal at: ukraine.resisting@gmail.com. *** Contents: 0:00:00 - Intro 0:02:24 - How does "The Road to Freedom" compare to Hayek's "The Road to Serfdom" and Snyder's "The Road to Unfreedom"? 0:02:45 - What are Stiglitz's main criticisms of neoliberalism? 0:08:09 - What's the core flaw in the concept of "limitless freedom"? 0:17:33 - How is Russia undermining democracy? 0:19:00 - What steps can Europe take with frozen Russian assets for Ukraine? 0:20:46 - Why won't seizing Russian assets cause a capital crisis or violate rule of law? 0:27:22 - How can good regulation foster beneficial innovation, not just exploitation?

In this episode of The Broadband Bunch, recorded live from Fiber Connect 2025, host Brad Hine sits down with Stephen Rose, CEO of Render Networks, for a conversation about the evolving broadband landscape and the role of intelligent infrastructure. Stephen shares his journey from global telecom operations to leading innovation at Render, drawing on past leadership roles at IBM, Nokia, and the Nobel Prize-winning Nokia Bell Labs. The discussion covers a wide range of topics—from Render's latest industry partnerships with EXFO and VETRO FiberMap, to the impact of AI and automation in fiber network deployment. Stephen emphasizes the need for data transparency, cross-industry collaboration, and scalable software ecosystems to address challenges like labor shortages, cost overruns, and operational inefficiencies. Listeners will also get insights into Render's growing influence beyond telecommunications, including electric and utility sectors, and how Render's platform continues to drive digital transformation even after network builds are complete.

In this eye-opening episode, discover the harsh reality behind why intelligent individuals often remain financially stagnant while others with seemingly fewer qualifications thrive. Matt explores the phenomenon where overplanning and fear of failure hold back smart people, referencing insights from Nobel Prize winners Daniel Kahneman and Herbert Simon, and featuring real-life success stories. It emphasizes the importance of taking bold, consistent action over striving for perfection. The episode also provides valuable resources, including a free guide to kickstart your wealth-building journey, and highlights the critical difference between thinkers and doers in achieving financial success. BUT BEFORE THAT, find out how Matt would go from ZERO rentals to owning 10 homes THIS YEAR! Useful links: https://www.notion.so/The-3-Property-Escape-Plan-220315cb4ef9809e9febe64c81d51f71 Learn more about your ad choices. Visit megaphone.fm/adchoices

Recorded at the 2025 Humans to the Moon and Mars Summit (H2M2) in Washington, D.C., this episode features two powerful conversations about the future of human space exploration. Hosted by Mat Kaplan, senior communications adviser at The Planetary Society, these panel discussions explore the scientific and diplomatic foundations guiding humanity’s journey beyond Earth. The first panel, Space Science: A Vital National Interest, features James Green, former NASA chief scientist and chair of the Explore Mars advisory board, James Garvin, chief scientist at NASA Goddard Space Flight Center, Britney Schmidt, astrobiologist and associate professor at Cornell University, and John Mather, Nobel Prize–winning astrophysicist and senior scientist for the James Webb Space Telescope. They discuss how space science drives innovation, strengthens U.S. national priorities, and deepens our understanding of the universe, especially in the face of proposed funding cuts. In the second panel, Artemis Accords: International Collaboration in Deep Space, Mike Gold of Redwire, Marc Jochemich of the German Aerospace Center (DLR), Adnan Mohammad Alrais of the Mohammed bin Rashid Space Centre, and Sohair Salam Saber of The Hague Institute for Global Justice explore how diplomacy and shared values are shaping global participation in lunar exploration. The conversation also highlights the Washington Compact, an effort to bring shared values and responsible behavior in space to commercial companies and other non-governmental organizations. We wrap up the show with a new What’s Up segment with Bruce Betts, where we talk about what could happen if the Gateway lunar space station is canceled, and how that would impact humanity’s dreams for Mars. Discover more at: https://www.planetary.org/planetary-radio/2025-H2M2See omnystudio.com/listener for privacy information.

"With the great power to invent technology comes a great responsibility." – In this lively and energetic podcast conversation, economic sciences laureate Simon Johnson talks about how the past, future and present are interconnected, as well as how science fiction and history are intertwined. He comes to the conclusion that “science fiction is history in reverse or history is science fiction in reverse, whichever way you want to think about it. He also tells us about his family history and how his family was part of the steel industry in Sheffield, England. The industrial revolution is discussed as well as the responsibility that comes with inventing technology. Through their lives and work, failures and successes – get to know the individuals who have been awarded the Nobel Prize on the Nobel Prize Conversations podcast. Find it on Acast, or wherever you listen to pods. https://linktr.ee/NobelPrizeConversations© Nobel Prize Outreach. Hosted on Acast. See acast.com/privacy for more information.

In the fifth of this six-part series of The Economics Show, Martin Wolf, the FT's chief economics commentator, and Nobel Prize-winning economist Paul Krugman discuss the way American politics is crashing against both the guardrails of a stable, democratic system and the rules and norms of the postwar economic order and how this could jeopardise the importance of the US on the world stage.Paul Krugman's Cultural Coda: Stephen Sondheim: "We had a good thing going"https://www.youtube.com/watch?v=NTbrbiM-slg&list=RDNTbrbiM-slg&start_radio=1Martin Wolf's Cultural Coda:Jonas Kaufmann: Freiheit from Beethoven's Fideliohttps://www.youtube.com/watch?v=GvfhmGsFMEoSubscribe and listen to this series on The Economics Show on Apple Podcasts, Spotify, Pocket Casts or wherever you listen to podcasts. Episodes are also available on the FT's YouTube channel.If you'd like to get in touch and ask Martin and Paul a question, please email economics.show@ft.com Read Martin's FT column hereSubscribe to Paul's substack hereThe Wolf-Krugman Exchange is produced by Sandra Kanthal. The broadcast engineer was Rod Fitzgerald. The sound engineer is Breen Turner. Manuela Saragosa is the FT's acting co-head of audio.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Special offer! Get 20% off discount to The Economist and all it has to offer! Visit https://www.economist.com/toe Harvard physicist Jacob Barandes returns with a groundbreaking insight that could reshape quantum theory. By questioning a single hidden assumption, Jacob bridges the gap between classical probability and quantum mechanics. This ‘mathematical accident' challenges the foundations of Bell's Theorem, dissolves the measurement problem, and opens a path to a realist interpretation of quantum physics. This episode is a rigorous journey through stochastic processes, non-locality, and the future of theoretical physics. Join My New Substack (Personal Writings): https://curtjaimungal.substack.com Listen on Spotify: https://open.spotify.com/show/4gL14b92xAErofYQA7bU4e Timestamps: 00:00 Introduction 1:01:46 Teaching Black Holes to Graduate Students 1:04:59 Coordinate Systems in Space-Time 1:06:58 Teaching Black Hole Coordinates 1:10:11 Insights from Nima 1:13:41 Nima's Course on Quantum Mechanics 1:16:22 Quantum Foundations and Cosmology 1:18:48 Transitioning to Quantum Gravity 1:23:10 Philosophy's Role in Physics 1:26:10 Leaving String Theory 1:33:39 Interpretations of Quantum Mechanics 1:37:02 Challenges of String Theory 1:42:49 Quantum Field Theory Insights 1:50:30 Foundations of Quantum Field Theory 1:53:47 Particle Existence Between Measurements 1:59:44 Speculations on Quantum Gravity 2:01:41 Legacy and Contributions Links Mentioned: •⁠ ⁠Press release of the 2022 Nobel Prize in Physics: https://www.nobelprize.org/uploads/2022/10/press-physicsprize2022-2.pdf •⁠ ⁠Eddy Chen & Barry Loewer on TOE: https://youtu.be/xZnafO__IZ0 •⁠ ⁠Jacob Barandes on TOE (part 1): https://youtu.be/7oWip00iXbo •⁠ ⁠Tim Maudlin on TOE: https://youtu.be/fU1bs5o3nss •⁠ ⁠What Is Real? (book): https://www.amazon.com/What-Real-Unfinished-Meaning-Quantum/dp/0465096050 •⁠ ⁠David Wallace on TOE: https://youtu.be/4MjNuJK5RzM •⁠ ⁠The Copenhagen Interpretation: https://plato.stanford.edu/entries/qm-copenhagen/ •⁠ ⁠Bohmian Mechanics: https://plato.stanford.edu/entries/qm-bohm/ •⁠ ⁠Everettian Quantum Mechanics: https://plato.stanford.edu/entries/qm-everett/ •⁠ ⁠Jacob Barandes on TOE (part 2): https://youtu.be/YaS1usLeXQM •⁠ ⁠Jacob Barandes on TOE (part 3): https://youtu.be/wrUvtqr4wOs •⁠ ⁠The sky is blue (paper): https://arxiv.org/pdf/2205.00568 •⁠ ⁠The Emergent Universe (book): https://www.amazon.com/Emergent-Multiverse-Quantum-according-Interpretation/dp/0198707541 •⁠ ⁠Complex Coordinates and Quantum Mechanics (paper): https://journals.aps.org/rmp/abstract/10.1103/RevModPhys.38.36 •⁠ ⁠Kurt Vonnegut's lecture: https://youtu.be/4_RUgnC1lm8 •⁠ ⁠Max Born's memoir: https://archive.org/details/myliferecollecti0000born/page/n5/mode/2up •⁠ ⁠Hugh Everett's unpublished dissertation: https://ia801909.us.archive.org/20/items/TheTheoryOfTheUniversalWaveFunction/The%20Theory%20of%20the%20Universal%20Wave%20Function.pdf •⁠ ⁠La nouvelle cuisine (paper): https://www.cambridge.org/core/books/abs/speakable-and-unspeakable-in-quantum-mechanics/la-nouvelle-cuisine/6FFC85D84585D9C41AA4A1185BF5290E •⁠ ⁠The Great Rift in Physics (paper): https://arxiv.org/pdf/2503.20067 •⁠ ⁠Quantum stochastic processes (paper): https://arxiv.org/pdf/2012.01894 •⁠ ⁠Bell's Theorem: https://plato.stanford.edu/entries/bell-theorem/ •⁠ ⁠Neil Turok on TOE: https://youtu.be/zNZCa1pVE20 ***For full resources please visit https://curtjaimungal.org SUPPORT: - Become a YouTube Member (Early Access Videos): https://www.youtube.com/channel/UCdWIQh9DGG6uhJk8eyIFl1w/join - Support me on Patreon: https://patreon.com/curtjaimungal - Support me on Crypto: https://commerce.coinbase.com/checkout/de803625-87d3-4300-ab6d-85d4258834a9 - Support me on PayPal: https://www.paypal.com/donate?hosted_button_id=XUBHNMFXUX5S4 SOCIALS: - Twitter: https://twitter.com/TOEwithCurt - Discord Invite: https://discord.com/invite/kBcnfNVwqs #science Learn more about your ad choices. Visit megaphone.fm/adchoices

Matt Abrahams's passion for communication was shaped by his parents during his childhood. In the corporate world, he noticed that great ideas often went unheard because people were too anxious to speak up, particularly in high-pressure situations. Realizing that fear, not a lack of ideas, was the barrier to success, Matt made it his mission to help individuals overcome anxiety and communicate with confidence. In this episode, Matt joins Ilana to share his top techniques for managing public speaking anxiety and how you can transition from rambling to speaking with clarity, confidence, and impact. Matt Abrahams is a bestselling author, communication coach, and lecturer at the Stanford Graduate School of Business. He has helped individuals deliver impactful presentations, from IPO roadshows to Nobel Prize speeches, TED Talks, and World Economic Forum sessions. In this episode, Ilana and Matt will discuss: (00:00) Introduction  (01:50) His Path to Becoming a Communication Expert (05:50) Corporate Lessons and the Transition to Teaching (09:36) Mastering Communication as a Teacher (12:54) Understanding and Managing Anxiety (18:19) Matt's Top Anxiety Management Techniques (23:15) The Keys to His Career Growth and Success (25:11) Turning Mistakes into Business Opportunities (28:49) Navigating Social Media and Feedback (33:29) How to Stop Rambling and Speak with Confidence (36:30) How to Understand and Connect with Your Audience Matt Abrahams is a bestselling author, communication coach, and lecturer at the Stanford Graduate School of Business. He is the author of Speaking Up Without Freaking Out and Think Faster, Talk Smarter, and host of the award-winning Think Fast, Talk Smart podcast. Matt has helped individuals deliver impactful presentations, from IPO roadshows to Nobel Prize speeches, TED Talks, and World Economic Forum sessions. Connect with Matt: Website: fastersmarter.io  LinkedIn: linkedin.com/in/maabrahams  Resources Mentioned: Matt's Book, Think Faster, Talk Smarter: How to Speak Successfully When You're Put on the Spot: https://www.amazon.com/Think-Faster-Talk-Smarter-Successfully/dp/1668010305  Matt's Book, Speaking Up without Freaking Out: 50 Techniques for Confident and Compelling Presenting: https://www.amazon.com/Speaking-without-Freaking-Out-Techniques/dp/1465290478  Matt's Podcast, Think Fast Talk Smart: https://podcasts.apple.com/us/podcast/think-fast-talk-smart-communication-techniques/id1494989268  Leap Academy: Ready to make the LEAP in your career? There is a NEW way for professionals to Advance Their Careers & Make 5-6 figures of EXTRA INCOME in Record Time. Check out our free training today at leapacademy.com/training

Today's Episode:She was American, but spoke Chinese like a native. She grew up in rural China, won the Nobel Prize, and told the world real stories about Chinese people. Who was Pearl S. Buck — and why did she love China so deeply? Let's find out in today's episode.Membership Preview:Crazy Chinese menu translations like “Fxxk and Explode Chicken” and “Husband and Wife Lung Slices” . What do they really mean?! Join the next MaoMi Chinese+ to laugh, learn, and uncover the surprising culture and language behind these hilarious English mistakes!Support MaoMi & Get exclusive   to premium content!https://www.buzzsprout.com/1426696/subscribe ↗️Transcript and translations are available on https://maomichinese.comInterested in any topics? Leave me a message on: https://maomichinese.com or https://www.instagram.com/maomichinese/?hl=en*Please note that Spotify does not support the membership program.Text me what you think :)Support the show

In this episode, Dr. Jockers explains how eating late at night blocks fat burning and disrupts metabolic function. Discover how this habit increases insulin resistance and affects your ability to burn fat.   Late-night eating also impacts your circadian rhythm, disrupting sleep and hormone balance. Poor sleep leads to more cravings and overeating.   Learn why eating three hours before bed is essential for fat burning and overall health. Dr. Jockers offers practical tips for shift workers to manage their eating schedule.     In This Episode:  02:33 The Number One Habit Blocking Fat Burning 03:36 The Science Behind Late-Night Eating 05:37 Health Risks of Eating Late at Night 09:11 Final Thoughts and Recommendations   Explore the health benefits of C60, a Nobel Prize-winning antioxidant that optimizes mitochondrial function and fights inflammation. Visit shopc60.com and discover how to boost your immune system, detox your body, and increase energy. Use promo code 'Jockers' for 15% off your first order. Start your journey to better health with C60 today!   If you're dealing with blood sugar swings, stubborn fat, or constant cravings, Berberine Breakthrough by BiOptimizers could be the game-changer your body needs. This advanced formula goes beyond standard berberine by combining it with 12 synergistic ingredients like alpha-lipoic acid, chromium, and cinnamon to supercharge your metabolism, stabilize insulin levels, and fuel mitochondrial health. Users report better energy, fewer cravings, and noticeable fat loss — all backed by science. Plus, it comes with a 365-day money-back guarantee, so there's zero risk. Use code JOCKERS at bioptimizers.com/jockers to save 10% and start transforming your health today.     “Eating late at night drives up inflammation, disrupts your circadian rhythm, and stops your body from burning fat.”  ~ Dr. Jockers     Subscribe to the podcast on: Apple Podcast Stitcher Spotify PodBean TuneIn Radio     Resources: Visit https://shopc60.com/jockers – Use code “JOCKERS” to get 15% off! Visit biOptimizers.com/Jockers     Connect with Dr. Jockers: Instagram – https://www.instagram.com/drjockers/ Facebook – https://www.facebook.com/DrDavidJockers YouTube – https://www.youtube.com/user/djockers Website – https://drjockers.com/ If you are interested in being a guest on the show, we would love to hear from you! Please contact us here! - https://drjockers.com/join-us-dr-jockers-functional-nutrition-podcast/ 

Abdulrazak Gurnah is emeritus Professor of Post-Colonial Literatures at the University of Kent and the 2021 Nobel Prize winner in Literature. Born in Zanzibar in 1948, the second of six children, Abdulrazak grew up in the dying days of the island's status as a British protectorate before independence was declared in 1963. The revolution which followed made Zanzibar an undesirable and unsafe place to live in for young men of Arab heritage. In 1967, he left to seek opportunities in Britain.He subsidised his studies through a series of low paid jobs which included strawberry picking, factory work and time as a hospital porter. In the evenings he was studying at night school and after gaining a PhD in English, he joined the University of Kent, eventually becoming a Professor.Alongside his academic career, Abdulrazak was writing and it took him twelve years to find a publisher for his 1987 debut novel, Memory of Departure.He has published ten more novels since then, including 1994's Paradise and 2001's By the Sea (short and longlisted for the Booker Prize respectively) which explore themes of exile, displacement, belonging and colonialism. He was awarded the 2021 Nobel Prize in Literature for his body of work and “for his uncompromising and compassionate penetration of the effects of colonialism and the fates of the refugee in the gulf between cultures and continents”. He lives in Kent, with his wife, the Guyanese-born scholar, Denise de Caires Narain. DISC ONE: Hit the Road Jack - Ray Charles DISC TWO: Petite Fleur - Sidney Bechet DISC THREE: Nipepee - Seif Salim DISC FOUR: Piano Concerto in A Minor, Op. 7 - 1. Allegro maestoso. Composed by Clara Schumann. Performed by Isata Kanneh-Mason (piano) and Royal Liverpool Philharmonic Orchestra, conducted by Holly Mathieson DISC FIVE: A Day in the Life - The Beatles DISC SIX: Kaira - Toumani Diabaté DISC SEVEN: So What - Miles Davis DISC EIGHT: Folon - Salif Keita BOOK CHOICE: That Glimpse of Truth: The 100 Finest Short Stories Ever Written selected by David Miller LUXURY ITEM: A nail clipper CASTAWAY'S FAVOURITE: Petite Fleur - Sidney Bechet Presenter Lauren Laverne Producer Sarah Taylor